INS and heart failure: When assessing baseline characteristics by comparator (Additional file 4: Appendix Table S4C), the proportion of subjects with heart failure, other prior CV events and prior insulin use was higher, and mean eGFR was lower, in the placebo and semaglutide groups than in the other comparator groups, driven by the large patient numbers and high baseline CV risk in the CVOTs.